We transform biological targets into procurement-ready molecular candidates — delivered in 48 to 72 hours.
The Industry Problem
The market is saturated with generative models producing theoretical structures — up to 90% of which cannot be synthesized, purchased, or tested within a reasonable timeframe.
ORAKLIS operates under a different doctrine. Our engine does not generate molecules. It performs Behavioral Molecular Profiling across 700,000+ commercially available compounds — natural and synthetic — and isolates candidates with confirmed thermodynamic engagement to your target. Every candidate we deliver is available for immediate procurement.
Verified Performance
LIT-PCBA is the industry's most rigorous decoy-free screening benchmark — specifically designed to eliminate the artificial enrichment that inflates most published results. Our protocol is verified against data leakage standards.
OPRK1 · LIT-PCBA Target
Enrichment Factor @ Top 1%
Top 1% of the library captured a substantial
fraction of all known OPRK1 actives.
OPRK1 — a G-protein-coupled opioid receptor — is one of the 15 targets of the LIT-PCBA benchmark. Our engine reached an Enrichment Factor of 62.5× on this target, evaluated under blind labeling conditions with no post-hoc tuning of hyperparameters. Across the 15 targets evaluated, 10 exceeded EF > 20× and 13 exceeded the EF > 5× significance threshold, with full transparency on the two targets that fell below.
Methodological Integrity · Why It Matters
Most published virtual screening results inflate performance through silent post-hoc tuning. Ours do not.
A single, frozen variant of the engine was applied uniformly to all 15 LIT-PCBA targets. Active/inactive labels were masked during ranking and revealed only for metric computation. Hyperparameters were locked before the benchmark run and never revisited. The two targets where the engine fell below the significance threshold are reported in the dossier as openly as the targets where it exceeded 30×. This discipline — rare in the field — is what allows a third-party reviewer to reproduce our claims without ambiguity.
Prospective experimental validation — laboratory partnerships in active engagement
Benchmark Highlights
The Three Offers
From new patentable scaffolds to resistance breakers. Each engagement delivers procurement-ready candidates under mutual NDA.
Identification of structurally distinct, patentable chemical families that bypass documented resistance mutations. Directly applicable to mecA, CYP51, MFS1 and other resistance mechanisms.
Natural equivalents to threatened or banned synthetic molecules — REACH-compliant, Clean Label approved, commercially available today. Applied across dermocosmetics, agrochemicals and material sciences.
Identification of a binary partner — Resistance Breaker or adjuvant — that neutralizes pathogen defense mechanisms and restores the original efficacy of clinical candidates. Analogous to Clavulanic Acid protecting Amoxicillin.
The Method
Every candidate we deliver is confirmed through a four-stage filtering protocol. Each stage is independently validated. No step is optional.
Atomic Engagement
Every deliverable includes atomic-resolution confirmation of binding within the target's catalytic pocket. Measured engagement. Validated residues. Zero probabilistic guesswork.
The Low-Data Advantage
Laboratories possessing 3,000 validated hits do not need computational screening — they are already in clinical phase. The "Big Data" obsession is a trap engineered by generic AI platforms.
Our engine operates in clinical reality — the Low-Data environment. Fifteen to thirty reference actives are sufficient to extract a strict behavioral fingerprint from the target. This is what allows us to deliver results in 48 to 72 hours while averaging methods require months of calibration and thousands of data points that do not exist yet in emerging targets.
Market Verticals
Precision engineering adapted to the constraints of each vertical. Our candidates are pre-filtered for regulatory compliance before delivery.
Resistance-driven obsolescence of clinical candidates. Patent landscape saturation. Multi-year synthesis bottlenecks in hit-to-lead phases.
REACH restrictions eliminating foundational ingredients. Clean Label regulatory acceleration. Demand for scientifically validated natural actives.
Fungal resistance mutations (Z. tritici, TR4). EU Farm to Fork restrictions. Urgent need for novel scaffolds with pollinator safety.
Engagement Models
Three engagement models aligned with your risk profile, IP objectives, and operational maturity. All engagements are under mutual NDA prior to any technical disclosure.
Fee-for-service single-target engagement. Discovery Report with 10 to 50 procurement-ready candidates delivered within 7 business days. Client retains 100% of resulting IP.
Priority access for laboratories with multiple active targets. Up to 5 runs per month. Double iteration loops between in-vitro feedback and computational re-prioritization.
Shared-risk partnership. ORAKLIS absorbs computational costs. Strict co-invention framework with milestones and royalties on commercialization.
Engagement scope, deliverable detail and investment are disclosed under mutual NDA
Operational Infrastructure
Natural and synthetic libraries — curated, validated, commercially accessible.
From target brief to full procurement-ready candidate list. No extensions.
Every candidate sourced from commercial catalogs. No generative hallucinations, no synthesis bottleneck.
All engagements begin with mutual NDA. Full IP protection throughout.
Deliver us one biological target. We return procurement-ready candidates within 48 to 72 hours. All engagements under mutual NDA. All deliverables catalog-orderable.
Fields below remain confidential. A mutual NDA precedes all technical disclosures.